APRE insider transaction filings
Aprea Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-17. Screen APRE transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for APRE between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Aprea Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-17 | 4 | Gruia Gabriela — Director | Grant/award (A): 3,135 @ $0 · Grant/award (A): 12,555 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Duey Marc — Director | Grant/award (A): 3,135 @ $0 · Grant/award (A): 12,555 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Pamukcu Rifat — Director | Grant/award (A): 3,135 @ $0 · Grant/award (A): 12,555 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Seizinger Bernd R. — Director | Grant/award (A): 3,135 @ $0 · Grant/award (A): 12,555 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Grissinger Michael — Director | Grant/award (A): 3,135 @ $0 · Grant/award (A): 12,555 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | Peters Richard — Director | Grant/award (A): 3,135 @ $0 · Grant/award (A): 12,555 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | BIZZARI JEAN-PIERRE — Director | Grant/award (A): 3,135 @ $0 · Grant/award (A): 12,555 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | HENNEMAN JOHN B III — Director | Grant/award (A): 3,135 @ $0 · Grant/award (A): 12,555 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Hamill John P. — SrVP/CFO/Prin Fin & Acct Ofcr | Purchase (P): 30,978 (derivative) @ $0.81 · Purchase (P): 30,978 (derivative) | EDGAR |
| 2026-04-01 | 4 | Peters Richard — Director | Purchase (P): 123,915 (derivative) @ $0.81 · Purchase (P): 123,915 (derivative) | EDGAR |
| 2026-03-16 | 4 | Gilad Oren — President/CEO, Director | Grant/award (A): 20,175 @ $0 · Grant/award (A): 80,700 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | Hamill John P. — SrVP/CFO/Prin Fin & Acct Ofcr | Grant/award (A): 10,095 @ $0 · Grant/award (A): 40,380 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Gilad Oren — President/CEO, Director | Purchase (P): 28,100 @ $0.89 · Purchase (P): 28,100 (derivative) | EDGAR |
| 2026-02-02 | 4 | Hamill John P. — SrVP/CFO/Prin Fin & Acct Ofcr | Purchase (P): 5,700 @ $0.89 · Purchase (P): 5,700 (derivative) | EDGAR |
| 2025-12-11 | 4 | Duey Marc — Director | Purchase (P): 21,459 @ $1.17 · Purchase (P): 21,459 (derivative) | EDGAR |
| 2025-12-11 | 4 | Gilad Oren — President/CEO, Director | Purchase (P): 21,459 (derivative) @ $1.17 · Purchase (P): 21,459 (derivative) | EDGAR |
| 2025-12-11 | 4 | Hamill John P. — SrVP/CFO/Prin Fin & Acct Ofcr | Purchase (P): 5,000 @ $1.17 · Purchase (P): 5,000 (derivative) | EDGAR |
| 2025-06-09 | 4 | Seizinger Bernd R. — Director | Grant/award (A): 1,045 @ $0 · Grant/award (A): 4,185 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Pamukcu Rifat — Director | Grant/award (A): 1,045 @ $0 · Grant/award (A): 4,185 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Gruia Gabriela — Director | Grant/award (A): 1,045 @ $0 · Grant/award (A): 4,185 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Duey Marc — Director | Grant/award (A): 1,045 @ $0 · Grant/award (A): 4,185 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Grissinger Michael — Director | Grant/award (A): 1,045 @ $0 · Grant/award (A): 4,185 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Peters Richard — Director | Grant/award (A): 1,045 @ $0 · Grant/award (A): 4,185 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | BIZZARI JEAN-PIERRE — Director | Grant/award (A): 1,045 @ $0 · Grant/award (A): 4,185 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | HENNEMAN JOHN B III — Director | Grant/award (A): 1,045 @ $0 · Grant/award (A): 4,185 (derivative) @ $0 | EDGAR |
| 2025-04-04 | 4 | Gilad Oren — President/CEO, Director | Purchase (P): 3,003 @ $1.87 · Purchase (P): 2,497 @ $1.80 | EDGAR |
| 2025-03-31 | 4 | Gilad Oren — President/CEO, Director | Grant/award (A): 6,725 @ $0 · Grant/award (A): 26,900 (derivative) @ $0 | EDGAR |
| 2025-03-31 | 4 | Hamill John P. — SrVP/CFO/Prin Fin & Acct Ofcr | Grant/award (A): 3,365 @ $0 · Grant/award (A): 13,460 (derivative) @ $0 | EDGAR |
| 2024-10-25 | 4 | Duey Marc — Director | Sale (S): 6,462 @ $4.58 | EDGAR |
| 2024-10-24 | 4 | Gilad Oren — President/CEO, Director | Purchase (P): 500 @ $3.92 | EDGAR |
| 2024-10-17 | 4 | Duey Marc — Director | Purchase (P): 30,000 @ $4.39 | EDGAR |
| 2024-10-16 | 4 | Gilad Oren — President/CEO, Director | Purchase (P): 250 @ $2.90 | EDGAR |
| 2024-10-16 | 4 | Duey Marc — Director | Purchase (P): 190 @ $2.58 | EDGAR |
| 2024-10-16 | 4 | Hamill John P. — SrVP/CFO/Prin Fin & Acct Ofcr | Purchase (P): 50 @ $2.46 | EDGAR |
| 2024-10-15 | 4 | Seizinger Bernd R. — Director | Purchase (P): 10,000 @ $2.68 | EDGAR |
| 2024-10-15 | 4 | Gilad Oren — President/CEO, Director | Purchase (P): 150 @ $2.54 · Purchase (P): 1,000 @ $2.59 | EDGAR |
| 2024-10-15 | 4 | Hamill John P. — SrVP/CFO/Prin Fin & Acct Ofcr | Purchase (P): 450 @ $2.61 | EDGAR |
| 2024-06-21 | 4 | Seizinger Bernd R. — Director | Grant/award (A): 1,045 @ $0 · Grant/award (A): 4,185 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Pamukcu Rifat — Director | Grant/award (A): 1,045 @ $0 · Grant/award (A): 4,185 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Duey Marc — Director | Grant/award (A): 1,045 @ $0 · Grant/award (A): 4,185 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Grissinger Michael — Director | Grant/award (A): 1,045 @ $0 · Grant/award (A): 4,185 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Peters Richard — Director | Grant/award (A): 1,045 @ $0 · Grant/award (A): 4,185 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | HENNEMAN JOHN B III — Director | Grant/award (A): 1,045 @ $0 · Grant/award (A): 4,185 (derivative) @ $0 | EDGAR |
| 2024-05-02 | 4 | Mirza Nadeem Q. — Chief Medical Officer | Grant/award (A): 6,730 @ $0 · Grant/award (A): 26,920 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | Gilad Oren — President, CEO, Director | Grant/award (A): 6,725 @ $0 · Grant/award (A): 26,900 (derivative) @ $0 | EDGAR |
| 2024-03-28 | 4 | Hamill John P. — SrVP/CFO/Prin Fin & Acct Ofcr | Grant/award (A): 3,365 @ $0 · Grant/award (A): 13,460 (derivative) @ $0 | EDGAR |
| 2024-03-14 | 4 | Seizinger Bernd R. — Director | Purchase (P): 6,860 @ $7.29 · Purchase (P): 3,430 (derivative) · Purchase (P): 3,430 (derivative) | EDGAR |
| 2024-03-14 | 4 | Gilad Oren — President, CEO, Director | Purchase (P): 2,000 @ $7.29 · Purchase (P): 1,000 (derivative) · Purchase (P): 1,000 (derivative) | EDGAR |
| 2024-03-14 | 4 | Hamill John P. — SrVP/CFO/Prin Fin & Acct Ofcr | Purchase (P): 1,010 @ $7.29 · Purchase (P): 505 (derivative) · Purchase (P): 505 (derivative) | EDGAR |
| 2024-03-14 | 4 | HENNEMAN JOHN B III — Director | Purchase (P): 6,860 @ $7.29 · Purchase (P): 3,430 (derivative) · Purchase (P): 3,430 (derivative) | EDGAR |
Recent 8-K events — Aprea Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-28 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-23 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-06-17 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-01 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-16 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-18 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=APRE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →